RE S EAR CH | R E P O R T S
Table 2. Seroconversion or fourfold increase in poliovirus antibody titer between days 0 and 28.
Type 1
6–11 months
5 years
10 years
Type 2
Intervention groups
n
% (95% CI)
Control IPV bOPV Control IPV bOPV Control IPV bOPV
1/34 34/41 5/35 2/64 56/57 8/62 0/87 87/91 39/92
2.9 (0.0–15.3) 82.9 (67.9–92.8) 14.3 (4.8–30.3) 3.1 (0.3–10.8) 98.2 (90.6–100) 12.9 (5.7–23.9) 0.0 (0.0–4.2) 95.6 (89.1–98.8) 42.4 (32.1–53.1)
P value
n
% (95% CI)
Ref 3/73 4.1 (0.9–11.5)
Table 2. Seroconversion or fourfold increase in poliovirus antibody titer between days 0 and 28.
Type 1
6–11 months
5 years
10 years
Type 2
Intervention groups
n
% (95% CI)
Control IPV bOPV Control IPV bOPV Control IPV bOPV
1/34 34/41 5/35 2/64 56/57 8/62 0/87 87/91 39/92
2.9 (0.0–15.3) 82.9 (67.9–92.8) 14.3 (4.8–30.3) 3.1 (0.3–10.8) 98.2 (90.6–100) 12.9 (5.7–23.9) 0.0 (0.0–4.2) 95.6 (89.1–98.8) 42.4 (32.1–53.1)
P value
n
% (95% CI)
Ref 3/73 4.1 (0.9–11.5)
